Biological
Anti-CD20 (rituximab)
Anti-CD20 (rituximab) is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
200%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
terminated133%
completed133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT06688331
terminatedphase_2
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
NCT00202930
completedphase_2
Rituximab in New Onset Type 1 Diabetes
NCT00279305
Clinical Trials (3)
Showing 3 of 3 trials
NCT06688331Phase 2
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT00202930Phase 2
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
NCT00279305Phase 2
Rituximab in New Onset Type 1 Diabetes
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3